Endpoints News
Novartis gets a win in MS Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
1 September, 2026
Endpoints 11 - Reserve Your Spot - Save $100 with our Early Bird rate
One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.
presented by Riyadh Global Medical Biotechnology
How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions
SPOTLIGHT
• 
top stories
1. Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors
2. Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
3. Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'
4. GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
5. Roche signs trispecific T cell engager pact with Simcere in another China deal
6. Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
7. ARCH Venture Partners targets $3 billion raise for latest fund
more stories
• 
Drew Armstrong
.

Endpoints broke the news last night of several deaths in trials of Novartis's CAR-T program. There's more to learn, and Nicole DeFeudis is working on the story today. Got a tip or a good theory? Email her at ndefeudis@endpoints.news
.
Drew Armstrong
Executive Editor, Endpoints News
@ArmstrongDrew
1
by Kyle LaHucik

At least 50 dif­fer­ent ven­ture in­vestors have ben­e­fit­ed from Eli Lil­ly’s deal­mak­ing this year, send­ing ear­ly in­vest­ment dol­lars back in­to the start­up ecosys­tem.

On Mon­day...

Read the full story
2
by Elizabeth Cairns

No­var­tis’ BTK in­hibitor Rhap­si­do has a chance of ex­pand­ing from a chron­ic itch treat­ment to the mul­ti­ple scle­ro­sis mar­ket fol­low­ing wins in two iden­ti­cal Phase...

Read the full story
3
by Andrew Dunn

Alu­mis' lead drug pro­gram suf­fered a clin­i­cal set­back Tues­day as the San Fran­cis­co biotech re­port­ed its TYK2 pill failed a mid-stage lu­pus study.

The re­sults...


Read the full story
4
by Reynald Castaneda

GSK on Tues­day said it will start a late-stage tri­al of its mR­NA vac­cine for sea­son­al in­fluen­za af­ter the can­di­date de­liv­ered “high­er im­mune re­spons­es” than...

Read the full story
5
by Kyle LaHucik

For the sec­ond time in as many weeks, Roche's busi­ness de­vel­op­ment team has lined up a deal with a Chi­nese bio­phar­ma.

The Swiss drug gi­ant...

Read the full story
6
by Nicole DeFeudis